Serum Monocyte Chemoattractant Protein-1 Concentrations Associate With Diabetes Status but Not Arterial Stiffness in Children With Type 1 Diabetes

  1. Issam Zineh, PHARMD1,
  2. Amber L. Beitelshees, PHARMD, MPH1,
  3. Janet H. Silverstein, MD2 and
  4. Michael J. Haller, MD, MS2
  1. 1Department of Pharmacy Practice and Center for Pharmacogenomics, University of Florida College of Pharmacy, Gainesville, Florida
  2. 2Division of Pediatric Endocrinology, Department of Pediatrics, University of Florida College of Medicine, Gainesville, Florida
  1. Corresponding author: Michael J. Haller, hallemj{at}peds.ufl.edu

Abstract

OBJECTIVE—The relationship between circulating markers of inflammation and arterial stiffness in children with type 1 diabetes is not well studied. We tested whether inflammatory monocyte chemoattractant protein (MCP)-1 concentrations correlate with arterial stiffness or type 1 diabetes status.

RESEARCH DESIGN AND METHODS—MCP-1 concentrations and radial tonometry data were available for 98 children with type 1 diabetes and 55 healthy control subjects. Arterial stiffness was calculated as augmentation index corrected for a heart rate of 75 (AI75). Correlation between MCP-1 and AI75 and differences in MCP-1 concentrations between case and control subjects were tested.

RESULTS—MCP-1 was significantly higher in children with type 1 diabetes than in control subjects (P < 0.001). However, there were no correlations between MCP-1 and AI75 in the overall sample or upon stratification by type 1 diabetes status (range P = 0.28–0.66).

CONCLUSIONS—Circulating MCP-1 was not associated with arterial stiffness but was significantly elevated in children with type 1 diabetes, indicating a proinflammatory state in children as young as 10 years. The clinical significance of MCP-1 elevation in type 1 diabetes needs further investigation.

Footnotes

  • Published ahead of print at http://care.diabetesjournals.org on 17 December 2008.

    Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. See http://creativecommons.org/licenses/by-nc-nd/3.0/ for details.

    The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked “advertisement” in accordance with 18 U.S.C Section 1734 solely to indicate this fact.

    • Accepted December 2, 2008.
    • Received October 10, 2008.
| Table of Contents

This Article

  1. Diabetes Care vol. 32 no. 3 465-467
  1. All Versions of this Article:
    1. dc08-1849v1
    2. 32/3/465 most recent